scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Stock Information for scPharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About scPharmaceuticals Inc.

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.